Company intelligence / Profile preview
Mulberry Biotherapeutics
Wellesley, Massachusetts, United Statesmulberrybio.com ↗
- Ownership
- Private
- Employees
- ~5
- Development stage
- Preclinical
01
Overview
Mulberry Biotherapeutics has demonstrated in animal models that intra-tumoral injection of attenuated S. typhimurium can decrease tumor volume through direct cytotoxic and antiangiogenic effects while also inducing a systemic immune response that targets distal tumors and prevents new lesion development. Preliminary efficacy has been shown in NF2 models as well as NF1 and meningioma animal models. No human clinical data reported.
- Therapeutic areas
- OncologyRare DiseasesNeurologyOther
- Modalities
- Bacteria-mediated therapy (attenuated S. typhimurium)
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Mulberry Biotherapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mulberry Biotherapeutics.